Aclaris Therapeutics Ownership 2024 | Who Owns Aclaris Therapeutics Now?
Institutional Ownership
42.00%
Insider Ownership
2.55%
Retail Ownership
55.45%
Institutional Holders
51.00
Aclaris Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | 13.26% | 7.68% | 9,395,934 | 8,742,827 | 1338.65% | 11,650,958 | Mar 31, 2024 |
| BLACKROCK INC. | 7.34% | 0.00% | 5,202,147 | -703,725 | -11.92% | 6,450,660 | Mar 31, 2024 |
| VANGUARD GROUP INC | 6.96% | 0.00% | 4,929,775 | 207,418 | 4.39% | 6,112,921 | Mar 31, 2024 |
| D. E. SHAW & CO., INC. | 4.63% | 0.00% | 3,282,982 | 1,343,972 | 69.31% | 4,070,898 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 4.62% | 0.00% | 3,273,492 | -205,869 | -5.92% | 4,059,130 | Mar 31, 2024 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 4.23% | 0.30% | 3,000,000 | -500,000 | -14.29% | 3,720,000 | Mar 31, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 3.89% | 0.09% | 2,753,495 | -245,000 | -8.17% | 3,414,334 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 3.01% | 0.01% | 2,135,367 | -216,040 | -9.19% | 2,646,000 | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 2.36% | 0.00% | 1,673,400 | -73,032 | -4.18% | 2,075,000 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.21% | 0.00% | 1,565,054 | 171,506 | 12.31% | 1,940,845 | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | 2.05% | 0.00% | 1,451,100 | 30,100 | 2.12% | 1,799,364 | Mar 31, 2024 |
| STATE STREET CORP | 1.89% | 0.00% | 1,338,439 | -50,000 | -3.60% | 1,659,664 | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | 1.88% | 0.00% | 1,329,616 | -133,845 | -9.15% | 1,648,724 | Mar 31, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 1.71% | 0.00% | 1,212,260 | -467,645 | -27.84% | 1,503,202 | Mar 31, 2024 |
| DEUTSCHE BANK AG\ | 1.35% | 0.00% | 957,021 | 22,975 | 2.46% | 1,186,706 | Mar 31, 2024 |
| CITADEL ADVISORS LLC | 1.31% | 0.00% | 930,003 | -4,458,786 | -82.74% | 1,153,203 | Mar 31, 2024 |
| SAMSARA BIOCAPITAL, LLC | 0.98% | 0.13% | 696,171 | - | - | 863,252 | Mar 31, 2024 |
| GSA CAPITAL PARTNERS LLP | 0.96% | 0.07% | 679,137 | -908,858 | -57.23% | 842,000 | Mar 31, 2024 |
| FMR LLC | 0.95% | 0.00% | 671,828 | 1,114 | 0.17% | 833,067 | Mar 31, 2024 |
| AQR CAPITAL MANAGEMENT LLC | 0.86% | 0.00% | 612,205 | 612,205 | 100.00% | 759,134 | Mar 31, 2024 |
Aclaris Therapeutics's largest institutional shareholder is BML CAPITAL MANAGEMENT, LLC, holding 13.26% of the company's total share outstanding, currently valued at $11.65M. The top 10 institutional shareholders own together 52.51% of the company.
Institutional Shareholders by % of Total Assets
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | 13.26% | 7.68% | 9,395,934 | 8,742,827 | 1338.65% | 11,650,958 | Mar 31, 2024 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 4.23% | 0.30% | 3,000,000 | -500,000 | -14.29% | 3,720,000 | Mar 31, 2024 |
| ACUITAS INVESTMENTS, LLC | 0.65% | 0.29% | 461,663 | 461,663 | 100.00% | 572,462 | Mar 31, 2024 |
| AISLING CAPITAL MANAGEMENT LP | 0.61% | 0.18% | 434,455 | - | - | 538,724 | Mar 31, 2024 |
| DEUTERIUM CAPITAL MANAGEMENT, LLC | 0.11% | 0.18% | 79,993 | 79,993 | 100.00% | 99,191 | Mar 31, 2024 |
| SAMSARA BIOCAPITAL, LLC | 0.98% | 0.13% | 696,171 | - | - | 863,252 | Mar 31, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 3.89% | 0.09% | 2,753,495 | -245,000 | -8.17% | 3,414,334 | Mar 31, 2024 |
| PALO ALTO INVESTORS LP | 0.80% | 0.08% | 569,832 | 569,832 | 100.00% | 706,592 | Mar 31, 2024 |
| GSA CAPITAL PARTNERS LLP | 0.96% | 0.07% | 679,137 | -908,858 | -57.23% | 842,000 | Mar 31, 2024 |
| XTX TOPCO LTD | 0.17% | 0.02% | 123,100 | -255,200 | -67.46% | 152,644 | Mar 31, 2024 |
| MARQUETTE ASSET MANAGEMENT, LLC | 0.12% | 0.02% | 83,979 | 83,979 | 100.00% | 104,134 | Mar 31, 2024 |
| FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 0.37% | 0.01% | 264,377 | - | - | 327,827 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 3.01% | 0.01% | 2,135,367 | -216,040 | -9.19% | 2,646,000 | Mar 31, 2024 |
| FNY INVESTMENT ADVISERS, LLC | 0.01% | 0.01% | 10,000 | 10,000 | 100.00% | 12,000 | Mar 31, 2024 |
| BBR PARTNERS, LLC | 0.08% | 0.01% | 60,000 | 60,000 | 100.00% | 74,400 | Mar 31, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | 0.04% | 0.01% | 30,984 | 30,984 | 100.00% | 38,000 | Mar 31, 2024 |
| TWO SIGMA ADVISERS, LP | 2.05% | 0.00% | 1,451,100 | 30,100 | 2.12% | 1,799,364 | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | 1.88% | 0.00% | 1,329,616 | -133,845 | -9.15% | 1,648,724 | Mar 31, 2024 |
| D. E. SHAW & CO., INC. | 4.63% | 0.00% | 3,282,982 | 1,343,972 | 69.31% | 4,070,898 | Mar 31, 2024 |
| RENAISSANCE TECHNOLOGIES LLC | 2.36% | 0.00% | 1,673,400 | -73,032 | -4.18% | 2,075,000 | Mar 31, 2024 |
The largest Aclaris Therapeutics shareholder by % of total assets is BML CAPITAL MANAGEMENT, LLC. The company owns 9.40M shares of Aclaris Therapeutics (ACRS), representing 7.68% of its total assets.
Institutional Buyers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| BML CAPITAL MANAGEMENT, LLC | 13.26% | 7.68% | 9,395,934 | 8,742,827 | 1338.65% | 11,650,958 | Mar 31, 2024 |
| D. E. SHAW & CO., INC. | 4.63% | 0.00% | 3,282,982 | 1,343,972 | 69.31% | 4,070,898 | Mar 31, 2024 |
| AQR CAPITAL MANAGEMENT LLC | 0.86% | 0.00% | 612,205 | 612,205 | 100.00% | 759,134 | Mar 31, 2024 |
| PALO ALTO INVESTORS LP | 0.80% | 0.08% | 569,832 | 569,832 | 100.00% | 706,592 | Mar 31, 2024 |
| ACUITAS INVESTMENTS, LLC | 0.65% | 0.29% | 461,663 | 461,663 | 100.00% | 572,462 | Mar 31, 2024 |
| VANGUARD GROUP INC | 6.96% | 0.00% | 4,929,775 | 207,418 | 4.39% | 6,112,921 | Mar 31, 2024 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.21% | 0.00% | 1,565,054 | 171,506 | 12.31% | 1,940,845 | Mar 31, 2024 |
| MAN GROUP PLC | 0.35% | 0.00% | 247,675 | 146,395 | 144.54% | 307,117 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.17% | - | 123,460 | 123,460 | 100.00% | 153,090 | Mar 31, 2024 |
| CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. | 0.14% | 0.00% | 100,773 | 100,773 | 100.00% | 124,959 | Mar 31, 2024 |
| MARQUETTE ASSET MANAGEMENT, LLC | 0.12% | 0.02% | 83,979 | 83,979 | 100.00% | 104,134 | Mar 31, 2024 |
| DEUTERIUM CAPITAL MANAGEMENT, LLC | 0.11% | 0.18% | 79,993 | 79,993 | 100.00% | 99,191 | Mar 31, 2024 |
| JANE STREET GROUP, LLC | 0.47% | 0.00% | 331,740 | 72,356 | 27.90% | 411,358 | Mar 31, 2024 |
| STRS OHIO | 0.37% | 0.00% | 264,700 | 71,700 | 37.15% | 328,000 | Mar 31, 2024 |
| RUSSELL INVESTMENTS GROUP, LTD. | 0.09% | 0.00% | 62,772 | 61,602 | 5265.13% | 77,837 | Mar 31, 2024 |
| BBR PARTNERS, LLC | 0.08% | 0.01% | 60,000 | 60,000 | 100.00% | 74,400 | Mar 31, 2024 |
| GROUP ONE TRADING, L.P. | 0.19% | 0.00% | 133,831 | 56,630 | 73.35% | 165,950 | Mar 31, 2024 |
| VERITION FUND MANAGEMENT LLC | 0.08% | 0.00% | 53,835 | 53,835 | 100.00% | 66,755 | Mar 31, 2024 |
| UBS GROUP AG | 0.10% | - | 70,401 | 50,777 | 258.75% | 87,297 | Mar 31, 2024 |
| HSBC HOLDINGS PLC | 0.07% | - | 46,358 | 46,358 | 100.00% | 57,484 | Mar 31, 2024 |
As of Mar 31 2024, Aclaris Therapeutics's largest institutional buyer is BML CAPITAL MANAGEMENT, LLC. The company purchased 8.74M stocks of ACRS, valued at $11.65M.
Institutional Sellers
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| CITADEL ADVISORS LLC | 1.31% | 0.00% | 930,003 | -4,458,786 | -82.74% | 1,153,203 | Mar 31, 2024 |
| VELAN CAPITAL INVESTMENT MANAGEMENT LP | - | - | - | -1,761,595 | -100.00% | - | Mar 31, 2024 |
| TANG CAPITAL MANAGEMENT LLC | - | - | - | -1,753,335 | -100.00% | - | Mar 31, 2024 |
| MONACO ASSET MANAGEMENT SAM | - | - | - | -979,399 | -100.00% | - | Mar 31, 2024 |
| GSA CAPITAL PARTNERS LLP | 0.96% | 0.07% | 679,137 | -908,858 | -57.23% | 842,000 | Mar 31, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | - | - | - | -748,775 | -100.00% | - | Mar 31, 2024 |
| BLACKROCK INC. | 7.34% | 0.00% | 5,202,147 | -703,725 | -11.92% | 6,450,660 | Mar 31, 2024 |
| BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC | 4.23% | 0.30% | 3,000,000 | -500,000 | -14.29% | 3,720,000 | Mar 31, 2024 |
| CITIGROUP INC | 0.02% | - | 12,335 | -495,173 | -97.57% | 15,295 | Mar 31, 2024 |
| MORGAN STANLEY | 0.69% | - | 491,666 | -484,213 | -49.62% | 609,665 | Mar 31, 2024 |
| QUBE RESEARCH & TECHNOLOGIES LTD | 1.71% | 0.00% | 1,212,260 | -467,645 | -27.84% | 1,503,202 | Mar 31, 2024 |
| CHECKPOINT CAPITAL L.P. | - | - | - | -453,614 | -100.00% | - | Mar 31, 2024 |
| GOLDMAN SACHS GROUP INC | 0.21% | - | 145,812 | -375,068 | -72.01% | 180,807 | Mar 31, 2024 |
| NUVEEN ASSET MANAGEMENT, LLC | 0.24% | 0.00% | 166,656 | -273,245 | -62.12% | 206,653 | Mar 31, 2024 |
| XTX TOPCO LTD | 0.17% | 0.02% | 123,100 | -255,200 | -67.46% | 152,644 | Mar 31, 2024 |
| ROCK SPRINGS CAPITAL MANAGEMENT LP | 3.89% | 0.09% | 2,753,495 | -245,000 | -8.17% | 3,414,334 | Mar 31, 2024 |
| ACADIAN ASSET MANAGEMENT LLC | 3.01% | 0.01% | 2,135,367 | -216,040 | -9.19% | 2,646,000 | Mar 31, 2024 |
| MILLENNIUM MANAGEMENT LLC | 4.62% | 0.00% | 3,273,492 | -205,869 | -5.92% | 4,059,130 | Mar 31, 2024 |
| CREDIT SUISSE AG/ | - | - | - | -135,629 | -100.00% | - | Mar 31, 2024 |
| TWO SIGMA INVESTMENTS, LP | 1.88% | 0.00% | 1,329,616 | -133,845 | -9.15% | 1,648,724 | Mar 31, 2024 |
As of Mar 31 2024, Aclaris Therapeutics's biggest institutional seller is CITADEL ADVISORS LLC. The company sold -4.46M shares of ACRS, valued at $1.15M.
Institutional New positions
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| AQR CAPITAL MANAGEMENT LLC | 0.86% | 0.00% | 612,205 | 612,205 | 100.00% | 759,134 | Mar 31, 2024 |
| PALO ALTO INVESTORS LP | 0.80% | 0.08% | 569,832 | 569,832 | 100.00% | 706,592 | Mar 31, 2024 |
| ACUITAS INVESTMENTS, LLC | 0.65% | 0.29% | 461,663 | 461,663 | 100.00% | 572,462 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.17% | - | 123,460 | 123,460 | 100.00% | 153,090 | Mar 31, 2024 |
| MARQUETTE ASSET MANAGEMENT, LLC | 0.12% | 0.02% | 83,979 | 83,979 | 100.00% | 104,134 | Mar 31, 2024 |
| DEUTERIUM CAPITAL MANAGEMENT, LLC | 0.11% | 0.18% | 79,993 | 79,993 | 100.00% | 99,191 | Mar 31, 2024 |
| BBR PARTNERS, LLC | 0.08% | 0.01% | 60,000 | 60,000 | 100.00% | 74,400 | Mar 31, 2024 |
| HARBOR CAPITAL ADVISORS, INC. | 0.04% | 0.01% | 30,984 | 30,984 | 100.00% | 38,000 | Mar 31, 2024 |
| TWO SIGMA SECURITIES, LLC | 0.02% | 0.00% | 16,114 | 16,114 | 100.00% | 19,981 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.02% | - | 15,700 | 15,700 | 100.00% | 19,468 | Mar 31, 2024 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.02% | - | 13,500 | 13,500 | 100.00% | 16,740 | Mar 31, 2024 |
| FNY INVESTMENT ADVISERS, LLC | 0.01% | 0.01% | 10,000 | 10,000 | 100.00% | 12,000 | Mar 31, 2024 |
| CORNERSTONE PLANNING GROUP LLC | 0.00% | 0.00% | 580 | 580 | 100.00% | 789 | Mar 31, 2024 |
| NELSON, VAN DENBURG & CAMPBELL WEALTH MANAGEMENT GROUP, LLC | - | - | 14 | 14 | 100.00% | 17 | Mar 31, 2024 |
Aclaris Therapeutics's largest new institutional shareholder by number of shares is AQR CAPITAL MANAGEMENT LLC, purchased 612.21K shares, valued at $759.13K, as of undefined.
Institutional Sold Out
| Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
|---|---|---|---|---|---|---|---|
| VELAN CAPITAL INVESTMENT MANAGEMENT LP | - | - | - | -1,761,595 | -100.00% | - | Mar 31, 2024 |
| TANG CAPITAL MANAGEMENT LLC | - | - | - | -1,753,335 | -100.00% | - | Mar 31, 2024 |
| MONACO ASSET MANAGEMENT SAM | - | - | - | -979,399 | -100.00% | - | Mar 31, 2024 |
| JACOBS LEVY EQUITY MANAGEMENT, INC | - | - | - | -748,775 | -100.00% | - | Mar 31, 2024 |
| CHECKPOINT CAPITAL L.P. | - | - | - | -453,614 | -100.00% | - | Mar 31, 2024 |
| CREDIT SUISSE AG/ | - | - | - | -135,629 | -100.00% | - | Mar 31, 2024 |
| LION POINT CAPITAL, LP | - | - | - | -115,898 | -100.00% | - | Mar 31, 2024 |
| UBS ASSET MANAGEMENT AMERICAS INC | - | - | - | -113,601 | -100.00% | - | Mar 31, 2024 |
| SWISS NATIONAL BANK | - | - | - | -108,900 | -100.00% | - | Mar 31, 2024 |
| OCTAGON CAPITAL ADVISORS LP | - | - | - | -100,000 | -100.00% | - | Mar 31, 2024 |
| ZURCHER KANTONALBANK (ZURICH CANTONALBANK) | - | - | - | -43,784 | -100.00% | - | Mar 31, 2024 |
| CHICAGO PARTNERS INVESTMENT GROUP LLC | - | - | - | -20,988 | -100.00% | - | Mar 31, 2024 |
| JANUS HENDERSON GROUP PLC | - | - | - | -20,300 | -100.00% | - | Mar 31, 2024 |
| WEXFORD CAPITAL LP | - | - | - | -20,000 | -100.00% | - | Mar 31, 2024 |
| IKARIAN CAPITAL, LLC | - | - | - | -19,482 | -100.00% | - | Mar 31, 2024 |
| BAYESIAN CAPITAL MANAGEMENT, LP | - | - | - | -17,800 | -100.00% | - | Mar 31, 2024 |
| ARIZONA STATE RETIREMENT SYSTEM | - | - | - | -13,853 | -100.00% | - | Mar 31, 2024 |
| OCCUDO QUANTITATIVE STRATEGIES LP | - | - | - | -13,504 | -100.00% | - | Mar 31, 2024 |
| TEACHER RETIREMENT SYSTEM OF TEXAS | - | - | - | -11,458 | -100.00% | - | Mar 31, 2024 |
| SQUAREPOINT OPS LLC | - | - | - | -10,378 | -100.00% | - | Mar 31, 2024 |
| GREAT WEST LIFE ASSURANCE CO /CAN/ | - | - | - | -1,944 | -100.00% | - | Mar 31, 2024 |
| LINDBROOK CAPITAL, LLC | - | - | - | -383 | -100.00% | - | Mar 31, 2024 |
| HUNTINGTON NATIONAL BANK | - | - | - | -334 | -100.00% | - | Mar 31, 2024 |
| ADVISORNET FINANCIAL, INC | - | - | - | -100 | -100.00% | - | Mar 31, 2024 |
| CAPTION MANAGEMENT, LLC | - | - | - | -100 | -100.00% | - | Mar 31, 2024 |
Aclaris Therapeutics's largest sold out institutional shareholder by shares sold is VELAN CAPITAL INVESTMENT MANAGEMENT LP, sold -1.76M shares, valued at -, as of undefined.
Aclaris Therapeutics Mutual Fund Holders
| Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
|---|---|---|---|---|---|
| HARTFORD HLS SERIES FUND II INC | 1.10% | 271,395 | - | - | Dec 31, 2023 |
| Humankind Benefit Corp | 0.23% | 5,203 | 4,496 | 635.93% | Dec 31, 2023 |
| VANGUARD VALLEY FORGE FUNDS | 0.09% | 44,964 | - | - | Dec 31, 2023 |
| VANGUARD HORIZON FUNDS | 0.07% | 1,413,008 | 1,413,008 | - | Dec 31, 2023 |
| FIDELITY COMMONWEALTH TRUST | 0.06% | 185,411 | 132,115 | 247.89% | Feb 29, 2024 |
| BRIDGEWAY FUNDS INC | 0.05% | 132,900 | - | - | Dec 29, 2023 |
| Federated Hermes MDT Series | 0.04% | 89,846 | - | - | Jan 31, 2024 |
| BlackRock Advantage SMID Cap Fund, Inc. | 0.03% | 6,060 | - | - | Dec 29, 2023 |
| BNY Mellon Strategic Funds, Inc. | 0.03% | 60,889 | - | - | Mar 31, 2024 |
| DEUTSCHE DWS INVESTMENTS VIT FUNDS | 0.02% | 10,759 | - | - | Dec 31, 2023 |
| T. Rowe Price Quantitative Management Funds, Inc. | 0.02% | 75,030 | - | - | Dec 31, 2023 |
| FIDELITY CAPITAL TRUST | 0.02% | 218,000 | - | - | Jan 31, 2024 |
| QUANTITATIVE MASTER SERIES LLC | 0.02% | 123,478 | 8,008 | 6.94% | Dec 31, 2023 |
| Gabelli Healthcare & WellnessRx Trust | 0.01% | 1,365 | - | - | Dec 29, 2023 |
| VANGUARD VARIABLE INSURANCE FUNDS | 0.01% | 447,911 | 447,911 | - | Dec 31, 2023 |
| Nushares ETF Trust | 0.01% | 60,443 | - | - | Jan 31, 2024 |
| VANGUARD INDEX FUNDS | 0.01% | 3,554,692 | 961,502 | 37.08% | Dec 31, 2023 |
| INVESCO EXCHANGE-TRADED FUND TRUST | 0.01% | 627,784 | - | - | Jan 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND | 0.01% | 134,507 | - | - | Dec 31, 2023 |
| TIAA SEPARATE ACCOUNT VA 1 | 0.01% | 1,604 | - | - | Dec 31, 2023 |
| FIDELITY SELECT PORTFOLIOS | 0.01% | 435,589 | - | - | Feb 29, 2024 |
| VANGUARD EXPLORER FUND | 0.01% | 73,649 | - | - | Jan 31, 2024 |
| DEUTSCHE DWS VARIABLE SERIES II | 0.01% | 12,953 | - | - | Dec 31, 2023 |
| MML SERIES INVESTMENT FUND | 0.00% | 43,885 | - | - | Dec 31, 2023 |
| ALPS ETF Trust | 0.00% | 50,005 | - | - | Feb 29, 2024 |
| HARTFORD SERIES FUND INC | 0.00% | 140,818 | - | - | Dec 31, 2023 |
| Calvert Variable Products, Inc. | 0.00% | 6,900 | - | - | Dec 31, 2023 |
| T. Rowe Price Index Trust, Inc. | 0.00% | 46,190 | - | - | Feb 29, 2024 |
| AdvisorShares Trust | 0.00% | 6,110 | - | - | Dec 29, 2023 |
| JPMORGAN INSURANCE TRUST | 0.00% | 26,398 | -1,102 | -4.01% | Mar 31, 2023 |
| NORTHWESTERN MUTUAL SERIES FUND INC | 0.00% | 241,684 | - | - | Dec 31, 2023 |
| FIDELITY CONCORD STREET TRUST | 0.00% | 392,278 | -155,308 | -28.36% | Feb 29, 2024 |
| MAINSTAY VP FUNDS TRUST | 0.00% | 217,727 | - | - | Dec 31, 2023 |
| SCHWAB STRATEGIC TRUST | 0.00% | 258,412 | -22,511 | -8.01% | Feb 29, 2024 |
| VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 40,404 | - | - | Dec 31, 2023 |
| FIDELITY SECURITIES FUND | 0.00% | 108,150 | - | - | Jan 31, 2024 |
| Forethought Variable Insurance Trust | 0.00% | 4,994 | - | - | Dec 29, 2023 |
| GOLDMAN SACHS VARIABLE INSURANCE TRUST | 0.00% | 4,438 | - | - | Dec 31, 2023 |
| Fidelity Commonwealth Trust II | 0.00% | 6,735 | - | - | Aug 31, 2023 |
| HARTFORD MUTUAL FUNDS II INC | 0.00% | 161,450 | - | - | Jan 31, 2024 |
| FIDELITY ADVISOR SERIES I | 0.00% | 176,350 | -222 | -0.13% | Feb 29, 2024 |
| Voya VARIABLE PORTFOLIOS INC | 0.00% | 28,525 | - | - | Dec 31, 2023 |
| LORD ABBETT SECURITIES TRUST | 0.00% | 4,200 | - | - | Jan 31, 2024 |
| TIAA-CREF LIFE FUNDS | 0.00% | 2,437 | - | - | Dec 31, 2023 |
| VARIABLE INSURANCE PRODUCTS FUND III | 0.00% | 7,300 | - | - | Dec 31, 2023 |
| STATE STREET VARIABLE INSURANCE SERIES FUNDS INC | 0.00% | 3,483 | - | - | Dec 31, 2023 |
| ADVISORS' INNER CIRCLE FUND | 0.00% | 9,954 | - | - | Jan 31, 2024 |
| Principal Exchange-Traded Funds | 0.00% | 8,922 | -1,375 | -13.35% | Mar 31, 2024 |
| VANGUARD WORLD FUND | 0.00% | 170,913 | 1,244 | 0.73% | Feb 29, 2024 |
| JOHN HANCOCK INVESTMENT TRUST | 0.00% | 51,862 | - | - | Jan 31, 2024 |
| Voya INVESTORS TRUST | 0.00% | 29,904 | - | - | Dec 31, 2023 |
| Meeder Funds | 0.00% | 2,383 | - | - | Mar 31, 2024 |
| SunAmerica Specialty Series | 0.00% | 256 | - | - | Apr 30, 2021 |
| SEASONS SERIES TRUST | 0.00% | 9,539 | - | - | Dec 31, 2023 |
| PFM Multi-Manager Series Trust | 0.00% | 300 | - | - | Dec 31, 2023 |
| Dimensional ETF Trust | 0.00% | 158,672 | - | - | Jan 31, 2024 |
| GPS Funds I | 0.00% | 1,831 | - | - | Dec 31, 2023 |
| VANGUARD QUANTITATIVE FUNDS | 0.00% | 3,104 | - | - | Dec 31, 2023 |
| Victory Portfolios II | 0.00% | 15,791 | - | - | Dec 31, 2023 |
| Guardian Variable Products Trust | 0.00% | 4,400 | - | - | Dec 31, 2023 |
| STATE STREET INSTITUTIONAL INVESTMENT TRUST | 0.00% | 22,437 | 2,700 | 13.68% | Dec 31, 2023 |
| RUSSELL INVESTMENT CO | 0.00% | 77,122 | - | - | Jan 31, 2024 |
| VARIABLE INSURANCE PRODUCTS FUND II | 0.00% | 2,853 | -1,506 | -34.55% | Dec 31, 2023 |
| iSHARES TRUST | 0.00% | 3,421,348 | - | - | Feb 29, 2024 |
| Trust for Advised Portfolios | 0.00% | 3,223 | - | - | Dec 31, 2023 |
| EQ ADVISORS TRUST | 0.00% | 186,185 | -44,671 | -19.35% | Dec 31, 2023 |
| VANGUARD SCOTTSDALE FUNDS | 0.00% | 316,329 | 37,439 | 13.42% | Feb 29, 2024 |
| MASSMUTUAL SELECT FUNDS | 0.00% | 159,843 | - | - | Dec 31, 2023 |
| DFA INVESTMENT DIMENSIONS GROUP INC | 0.00% | 155,201 | - | - | Jan 31, 2024 |
| RYDEX SERIES FUNDS | 0.00% | 633 | - | - | Dec 31, 2023 |
| LoCorr Investment Trust | 0.00% | 3,773 | - | - | Mar 31, 2024 |
| COLLEGE RETIREMENT EQUITIES FUND | 0.00% | 171,401 | 38,970 | 29.43% | Dec 31, 2023 |
| OHIO NATIONAL FUND INC | 0.00% | 2,837 | -7,879 | -73.53% | Dec 31, 2023 |
| Blackstone Alternative Investment Funds | 0.00% | 15,500 | 13,900 | 868.75% | Dec 31, 2023 |
| ProFunds | 0.00% | 990 | 406 | 69.52% | Jan 31, 2024 |
| VALIC Co I | 0.00% | 26,654 | -107 | -0.40% | Feb 29, 2024 |
| NATIONWIDE MUTUAL FUNDS | 0.00% | 10,417 | -595 | -5.40% | Jan 31, 2024 |
| NATIONWIDE VARIABLE INSURANCE TRUST | 0.00% | 10,643 | -7,445 | -41.16% | Dec 31, 2023 |
| RYDEX DYNAMIC FUNDS | 0.00% | 314 | - | - | Dec 31, 2023 |
| PENN SERIES FUNDS INC | 0.00% | 2,100 | - | - | Dec 29, 2023 |
| PROSHARES TRUST | 0.00% | 15,469 | 1,981 | 14.69% | Feb 29, 2024 |
| AMERICAN CENTURY ETF TRUST | 0.00% | 6,867 | - | - | Feb 29, 2024 |
| HARTFORD MUTUAL FUNDS INC/CT | 0.00% | 487,136 | - | - | Jan 31, 2024 |
| ALLIANZ VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 3,143 | - | - | Dec 31, 2023 |
| GOLDMAN SACHS TRUST | 0.00% | 8,555 | - | - | Feb 29, 2024 |
| Goldman Sachs ETF Trust | 0.00% | 5,008 | - | - | Feb 29, 2024 |
| Guggenheim Active Allocation Fund | 0.00% | 299 | - | - | Feb 29, 2024 |
| Invesco Exchange-Traded Self-Indexed Fund Trust | 0.00% | 10,908 | - | - | Feb 29, 2024 |
| Direxion Shares ETF Trust | 0.00% | 6,514 | - | - | Jan 31, 2024 |
| MASTER INVESTMENT PORTFOLIO | 0.00% | 3,568 | - | - | Dec 31, 2023 |
| Legg Mason Global Asset Management Trust | 0.00% | 36,000 | - | - | Jan 31, 2024 |
| NORTHERN FUNDS | 0.00% | 34,190 | - | - | Dec 29, 2023 |
| RYDEX VARIABLE TRUST | 0.00% | 41 | - | - | Dec 31, 2023 |
| FIRST TRUST EXCHANGE-TRADED FUND | 0.00% | 272 | - | - | Dec 31, 2023 |
| LINCOLN VARIABLE INSURANCE PRODUCTS TRUST | 0.00% | 57,200 | -22,473 | -28.21% | Dec 31, 2023 |
| MORGAN STANLEY PATHWAY FUNDS | 0.00% | 2,445 | - | - | Feb 29, 2024 |
| ADVANCED SERIES TRUST | 0.00% | 95,132 | - | - | Dec 29, 2023 |
| SUNAMERICA SERIES TRUST | 0.00% | 7,869 | -3,851 | -32.86% | Jan 31, 2024 |
| Brinker Capital Destinations Trust | 0.00% | 1,273 | - | - | Feb 29, 2024 |
| ALLSPRING MASTER TRUST | 0.00% | 1,282 | - | - | Feb 29, 2024 |
Aclaris Therapeutics's largest mutual fund holder by % of total assets is "HARTFORD HLS SERIES FUND II INC", owning 271.39K shares, compromising 1.10% of its total assets.
Aclaris Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
| Date | Holdings | Change % |
|---|---|---|
| 31 Mar, 24 | 51 | -51.43% |
| 31 Dec, 23 | 105 | -33.54% |
| 30 Sep, 23 | 158 | 7.48% |
| 30 Jun, 23 | 147 | -13.53% |
| 31 Mar, 23 | 170 | 31.78% |
| 31 Dec, 22 | 129 | 4.03% |
| 30 Sep, 22 | 124 | 10.71% |
| 30 Jun, 22 | 112 | 0.90% |
| 31 Mar, 22 | 111 | -17.78% |
| 31 Dec, 21 | 135 | 3.85% |
| 30 Sep, 21 | 130 | -3.70% |
| 30 Jun, 21 | 135 | 32.35% |
| 31 Mar, 21 | 102 | 22.89% |
| 31 Dec, 20 | 83 | 53.70% |
| 30 Sep, 20 | 54 | -6.90% |
| 30 Jun, 20 | 58 | -13.43% |
| 31 Mar, 20 | 67 | -10.67% |
| 31 Dec, 19 | 75 | -2.60% |
| 30 Sep, 19 | 77 | -6.10% |
| 30 Jun, 19 | 82 | -10.87% |
| 31 Mar, 19 | 92 | -4.17% |
| 31 Dec, 18 | 96 | 15.66% |
| 30 Sep, 18 | 83 | -10.75% |
| 30 Jun, 18 | 93 | -6.06% |
| 31 Mar, 18 | 99 | -1.98% |
| 31 Dec, 17 | 101 | -3.81% |
| 30 Sep, 17 | 105 | 0.96% |
| 30 Jun, 17 | 104 | -8.77% |
| 31 Mar, 17 | 114 | 14.00% |
| 31 Dec, 16 | 100 | 69.49% |
| 30 Sep, 16 | 59 | 22.92% |
| 30 Jun, 16 | 48 | 41.18% |
| 31 Mar, 16 | 34 | 3.03% |
| 31 Dec, 15 | 33 | - |
As of 31 Mar 24, 51 institutions are holding Aclaris Therapeutics's shares, representing a decrease of -51.43% compared to the previous quarter.
Shares Outstanding Trend
| Date | Shares Outstanding | Change % |
|---|---|---|
| 31 Mar, 24 | 29,764,046 | -48.96% |
| 31 Dec, 23 | 58,316,923 | -16.63% |
| 30 Sep, 23 | 69,947,964 | -1.60% |
| 30 Jun, 23 | 71,082,847 | -0.70% |
| 31 Mar, 23 | 71,582,171 | 8.58% |
| 31 Dec, 22 | 65,928,675 | 3.75% |
| 30 Sep, 22 | 63,546,338 | 0.44% |
| 30 Jun, 22 | 63,269,842 | 6.58% |
| 31 Mar, 22 | 59,362,942 | 5.96% |
| 31 Dec, 21 | 56,022,392 | -1.32% |
| 30 Sep, 21 | 56,773,128 | 1.50% |
| 30 Jun, 21 | 55,933,556 | 24.41% |
| 31 Mar, 21 | 44,958,313 | 41.27% |
| 31 Dec, 20 | 31,823,507 | 24.53% |
| 30 Sep, 20 | 25,554,120 | -10.21% |
| 30 Jun, 20 | 28,460,085 | -11.30% |
| 31 Mar, 20 | 32,087,370 | 4.21% |
| 31 Dec, 19 | 30,791,128 | 5.99% |
| 30 Sep, 19 | 29,051,072 | -18.28% |
| 30 Jun, 19 | 35,547,373 | -6.12% |
| 31 Mar, 19 | 37,865,881 | -3.06% |
| 31 Dec, 18 | 39,060,184 | 31.69% |
| 30 Sep, 18 | 29,659,852 | -4.25% |
| 30 Jun, 18 | 30,976,275 | 0.92% |
| 31 Mar, 18 | 30,693,525 | 7.91% |
| 31 Dec, 17 | 28,444,690 | -0.20% |
| 30 Sep, 17 | 28,502,746 | 11.30% |
| 30 Jun, 17 | 25,609,947 | 5.04% |
| 31 Mar, 17 | 24,381,279 | 14.19% |
| 31 Dec, 16 | 21,351,910 | 37.66% |
| 30 Sep, 16 | 15,510,243 | 0.75% |
| 30 Jun, 16 | 15,395,154 | 5.41% |
| 31 Mar, 16 | 14,605,450 | 41.96% |
| 31 Dec, 15 | 10,288,591 | - |
Aclaris Therapeutics (ACRS) has 29.76M shares outstanding as of 31 Mar 24, down -48.96% compared to the previous quarter.
Institutional Ownership Trend
| Date | Ownership % | Change % |
|---|---|---|
| 31 Mar, 24 | 42.00% | 0.62% |
| 31 Dec, 23 | 82.36% | 0.84% |
| 30 Sep, 23 | 99.03% | 0.88% |
| 30 Jun, 23 | 106.30% | 0.93% |
| 31 Mar, 23 | 107.04% | 1.10% |
| 31 Dec, 22 | 98.86% | 1.09% |
| 30 Sep, 22 | 95.31% | 1.04% |
| 30 Jun, 22 | 95.88% | 1.03% |
| 31 Mar, 22 | 96.63% | 1.15% |
| 31 Dec, 21 | 91.50% | 1.06% |
| 30 Sep, 21 | 92.74% | 0.86% |
| 30 Jun, 21 | 103.64% | 1.30% |
| 31 Mar, 21 | 89.31% | 1.68% |
| 31 Dec, 20 | 73.01% | 2.05% |
| 30 Sep, 20 | 59.70% | 1.31% |
| 30 Jun, 20 | 67.55% | 1.14% |
| 31 Mar, 20 | 77.10% | 1.39% |
| 31 Dec, 19 | 74.51% | 1.51% |
| 30 Sep, 19 | 70.23% | 0.95% |
| 30 Jun, 19 | 86.12% | 1.02% |
| 31 Mar, 19 | 91.80% | 0.90% |
| 31 Dec, 18 | 100.77% | 1.10% |
| 30 Sep, 18 | 95.73% | 0.96% |
| 30 Jun, 18 | 100.10% | 1.01% |
| 31 Mar, 18 | 99.38% | 1.17% |
| 31 Dec, 17 | 92.24% | 0.94% |
| 30 Sep, 17 | 98.85% | 1.07% |
| 30 Jun, 17 | 96.30% | 1.10% |
| 31 Mar, 17 | 93.48% | 1.12% |
| 31 Dec, 16 | 91.28% | 1.74% |
| 30 Sep, 16 | 72.42% | 1.30% |
| 30 Jun, 16 | 74.51% | 1.42% |
| 31 Mar, 16 | 72.41% | 2.18% |
| 31 Dec, 15 | 57.70% | - |
As of 31 Mar 24, Aclaris Therapeutics is held by 42.00% institutional shareholders, representing a 0.62% growth compared to 31 Dec 23.
Institutional Increased Positions Trend
| Date | Increased Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 28 | -54.10% |
| 31 Dec, 23 | 61 | -27.38% |
| 30 Sep, 23 | 84 | 23.53% |
| 30 Jun, 23 | 68 | -19.05% |
| 31 Mar, 23 | 84 | 40.00% |
| 31 Dec, 22 | 60 | -9.09% |
| 30 Sep, 22 | 66 | 8.20% |
| 30 Jun, 22 | 61 | 29.79% |
| 31 Mar, 22 | 47 | -39.74% |
| 31 Dec, 21 | 78 | 11.43% |
| 30 Sep, 21 | 70 | -22.22% |
| 30 Jun, 21 | 90 | 38.46% |
| 31 Mar, 21 | 65 | 44.44% |
| 31 Dec, 20 | 45 | 164.71% |
| 30 Sep, 20 | 17 | -29.17% |
| 30 Jun, 20 | 24 | -14.29% |
| 31 Mar, 20 | 28 | -15.15% |
| 31 Dec, 19 | 33 | -2.94% |
| 30 Sep, 19 | 34 | -24.44% |
| 30 Jun, 19 | 45 | -10.00% |
| 31 Mar, 19 | 50 | -23.08% |
| 31 Dec, 18 | 65 | 75.68% |
| 30 Sep, 18 | 37 | -27.45% |
| 30 Jun, 18 | 51 | -16.39% |
| 31 Mar, 18 | 61 | 7.02% |
| 31 Dec, 17 | 57 | -12.31% |
| 30 Sep, 17 | 65 | -9.72% |
| 30 Jun, 17 | 72 | 1.41% |
| 31 Mar, 17 | 71 | -20.22% |
| 31 Dec, 16 | 89 | 128.21% |
| 30 Sep, 16 | 39 | -2.50% |
| 30 Jun, 16 | 40 | 81.82% |
| 31 Mar, 16 | 22 | -33.33% |
| 31 Dec, 15 | 33 | - |
28 institutional shareholders have increased their position in ACRS stock as of 31 Mar 24 compared to 61 in the previous quarter (a -54.10% decrease).
Institutional Reduced Positions Trend
| Date | Reduced Positions | Change % |
|---|---|---|
| 31 Mar, 24 | 17 | -34.62% |
| 31 Dec, 23 | 26 | -27.78% |
| 30 Sep, 23 | 36 | -5.26% |
| 30 Jun, 23 | 38 | -9.52% |
| 31 Mar, 23 | 42 | 16.67% |
| 31 Dec, 22 | 36 | 44.00% |
| 30 Sep, 22 | 25 | -7.41% |
| 30 Jun, 22 | 27 | -38.64% |
| 31 Mar, 22 | 44 | 25.71% |
| 31 Dec, 21 | 35 | -5.41% |
| 30 Sep, 21 | 37 | 27.59% |
| 30 Jun, 21 | 29 | 16.00% |
| 31 Mar, 21 | 25 | 13.64% |
| 31 Dec, 20 | 22 | 10.00% |
| 30 Sep, 20 | 20 | - |
| 30 Jun, 20 | 20 | -13.04% |
| 31 Mar, 20 | 23 | -8.00% |
| 31 Dec, 19 | 25 | -7.41% |
| 30 Sep, 19 | 27 | - |
| 30 Jun, 19 | 27 | 12.50% |
| 31 Mar, 19 | 24 | 20.00% |
| 31 Dec, 18 | 20 | -25.93% |
| 30 Sep, 18 | 27 | -3.57% |
| 30 Jun, 18 | 28 | 3.70% |
| 31 Mar, 18 | 27 | -20.59% |
| 31 Dec, 17 | 34 | 30.77% |
| 30 Sep, 17 | 26 | 18.18% |
| 30 Jun, 17 | 22 | -33.33% |
| 31 Mar, 17 | 33 | 371.43% |
| 31 Dec, 16 | 7 | -30.00% |
| 30 Sep, 16 | 10 | 100.00% |
| 30 Jun, 16 | 5 | -16.67% |
| 31 Mar, 16 | 6 | - |
| 31 Dec, 15 | - | - |
17 institutional shareholders have reduced their position in ACRS stock as of 31 Mar 24 compared to 26 in the previous quarter (a -34.62% decrease).
All Institutional Ownership Trend Data
| Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| 31 Mar, 24 | 51 | -51.43% | 29,764,046 | -48.96% | 42.00% | 0.62% | 28 | -54.10% | 17 | -34.62% |
| 31 Dec, 23 | 105 | -33.54% | 58,316,923 | -16.63% | 82.36% | 0.84% | 61 | -27.38% | 26 | -27.78% |
| 30 Sep, 23 | 158 | 7.48% | 69,947,964 | -1.60% | 99.03% | 0.88% | 84 | 23.53% | 36 | -5.26% |
| 30 Jun, 23 | 147 | -13.53% | 71,082,847 | -0.70% | 106.30% | 0.93% | 68 | -19.05% | 38 | -9.52% |
| 31 Mar, 23 | 170 | 31.78% | 71,582,171 | 8.58% | 107.04% | 1.10% | 84 | 40.00% | 42 | 16.67% |
| 31 Dec, 22 | 129 | 4.03% | 65,928,675 | 3.75% | 98.86% | 1.09% | 60 | -9.09% | 36 | 44.00% |
| 30 Sep, 22 | 124 | 10.71% | 63,546,338 | 0.44% | 95.31% | 1.04% | 66 | 8.20% | 25 | -7.41% |
| 30 Jun, 22 | 112 | 0.90% | 63,269,842 | 6.58% | 95.88% | 1.03% | 61 | 29.79% | 27 | -38.64% |
| 31 Mar, 22 | 111 | -17.78% | 59,362,942 | 5.96% | 96.63% | 1.15% | 47 | -39.74% | 44 | 25.71% |
| 31 Dec, 21 | 135 | 3.85% | 56,022,392 | -1.32% | 91.50% | 1.06% | 78 | 11.43% | 35 | -5.41% |
| 30 Sep, 21 | 130 | -3.70% | 56,773,128 | 1.50% | 92.74% | 0.86% | 70 | -22.22% | 37 | 27.59% |
| 30 Jun, 21 | 135 | 32.35% | 55,933,556 | 24.41% | 103.64% | 1.30% | 90 | 38.46% | 29 | 16.00% |
| 31 Mar, 21 | 102 | 22.89% | 44,958,313 | 41.27% | 89.31% | 1.68% | 65 | 44.44% | 25 | 13.64% |
| 31 Dec, 20 | 83 | 53.70% | 31,823,507 | 24.53% | 73.01% | 2.05% | 45 | 164.71% | 22 | 10.00% |
| 30 Sep, 20 | 54 | -6.90% | 25,554,120 | -10.21% | 59.70% | 1.31% | 17 | -29.17% | 20 | - |
| 30 Jun, 20 | 58 | -13.43% | 28,460,085 | -11.30% | 67.55% | 1.14% | 24 | -14.29% | 20 | -13.04% |
| 31 Mar, 20 | 67 | -10.67% | 32,087,370 | 4.21% | 77.10% | 1.39% | 28 | -15.15% | 23 | -8.00% |
| 31 Dec, 19 | 75 | -2.60% | 30,791,128 | 5.99% | 74.51% | 1.51% | 33 | -2.94% | 25 | -7.41% |
| 30 Sep, 19 | 77 | -6.10% | 29,051,072 | -18.28% | 70.23% | 0.95% | 34 | -24.44% | 27 | - |
| 30 Jun, 19 | 82 | -10.87% | 35,547,373 | -6.12% | 86.12% | 1.02% | 45 | -10.00% | 27 | 12.50% |
| 31 Mar, 19 | 92 | -4.17% | 37,865,881 | -3.06% | 91.80% | 0.90% | 50 | -23.08% | 24 | 20.00% |
| 31 Dec, 18 | 96 | 15.66% | 39,060,184 | 31.69% | 100.77% | 1.10% | 65 | 75.68% | 20 | -25.93% |
| 30 Sep, 18 | 83 | -10.75% | 29,659,852 | -4.25% | 95.73% | 0.96% | 37 | -27.45% | 27 | -3.57% |
| 30 Jun, 18 | 93 | -6.06% | 30,976,275 | 0.92% | 100.10% | 1.01% | 51 | -16.39% | 28 | 3.70% |
| 31 Mar, 18 | 99 | -1.98% | 30,693,525 | 7.91% | 99.38% | 1.17% | 61 | 7.02% | 27 | -20.59% |
| 31 Dec, 17 | 101 | -3.81% | 28,444,690 | -0.20% | 92.24% | 0.94% | 57 | -12.31% | 34 | 30.77% |
| 30 Sep, 17 | 105 | 0.96% | 28,502,746 | 11.30% | 98.85% | 1.07% | 65 | -9.72% | 26 | 18.18% |
| 30 Jun, 17 | 104 | -8.77% | 25,609,947 | 5.04% | 96.30% | 1.10% | 72 | 1.41% | 22 | -33.33% |
| 31 Mar, 17 | 114 | 14.00% | 24,381,279 | 14.19% | 93.48% | 1.12% | 71 | -20.22% | 33 | 371.43% |
| 31 Dec, 16 | 100 | 69.49% | 21,351,910 | 37.66% | 91.28% | 1.74% | 89 | 128.21% | 7 | -30.00% |
| 30 Sep, 16 | 59 | 22.92% | 15,510,243 | 0.75% | 72.42% | 1.30% | 39 | -2.50% | 10 | 100.00% |
| 30 Jun, 16 | 48 | 41.18% | 15,395,154 | 5.41% | 74.51% | 1.42% | 40 | 81.82% | 5 | -16.67% |
| 31 Mar, 16 | 34 | 3.03% | 14,605,450 | 41.96% | 72.41% | 2.18% | 22 | -33.33% | 6 | - |
| 31 Dec, 15 | 33 | - | 10,288,591 | - | 57.70% | - | 33 | - | - | - |
Aclaris Therapeutics Insider Shareholders Trades
Open Market Insider Trades
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Open Market Insider Buys
| Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
|---|
Insider Sells
All Insider Owners Trades
The last insider sell of Aclaris Therapeutics's stock was made by Walker Neal on May 03 2024, selling 2,784 shares at $1.26 per share (valued at $3.51K).
Aclaris Therapeutics Insider Ownership Trends
All Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | 2 | 4 | 50.00% |
| Q1 2024 | 25 | 24 | 104.17% |
| Q4 2023 | - | 1 | - |
| Q3 2023 | 5 | 7 | 71.43% |
| Q2 2023 | 27 | 12 | 225.00% |
| Q1 2023 | 25 | 31 | 80.65% |
| Q4 2022 | - | 14 | - |
| Q3 2022 | 4 | - | - |
| Q2 2022 | 25 | 13 | 192.31% |
| Q1 2022 | 24 | 20 | 120.00% |
| Q4 2021 | 1 | 2 | 50.00% |
| Q3 2021 | 2 | 4 | 50.00% |
| Q2 2021 | 24 | 47 | 51.06% |
| Q1 2021 | 21 | 25 | 84.00% |
| Q4 2020 | 3 | 6 | 50.00% |
| Q3 2020 | 3 | 4 | 75.00% |
| Q2 2020 | 18 | 14 | 128.57% |
| Q1 2020 | 35 | 23 | 152.17% |
| Q4 2019 | 7 | 12 | 58.33% |
| Q3 2019 | 2 | 2 | 100.00% |
2 total buy trades, and 4 total sell trades (buy/sell ratio of 0.50%) were made by Aclaris Therapeutics's insiders, as of Q2 2024.
Open Market Insider Trades Trend
| Date | Buy | Sell | Buy/Sell Ratio |
|---|---|---|---|
| Q2 2024 | - | - | - |
| Q1 2024 | 2 | - | - |
| Q4 2023 | - | 1 | - |
| Q3 2023 | 2 | 1 | 200.00% |
| Q2 2023 | - | 1 | - |
| Q1 2023 | 2 | 16 | 12.50% |
| Q4 2022 | - | 13 | - |
| Q3 2022 | - | - | - |
| Q2 2022 | - | 5 | - |
| Q1 2022 | - | 6 | - |
| Q4 2021 | - | - | - |
| Q3 2021 | - | 1 | - |
| Q2 2021 | - | 33 | - |
| Q1 2021 | - | - | - |
| Q4 2020 | - | - | - |
| Q3 2020 | - | - | - |
| Q2 2020 | - | - | - |
| Q1 2020 | - | - | - |
| Q4 2019 | - | - | - |
| Q3 2019 | - | - | - |
As of Q2 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Aclaris Therapeutics's stocks.
Aclaris Therapeutics Peer Ownership
| Ticker | Company |
|---|---|
| GTH | Genetron Holdings Limited |
| QGEN | Qiagen N.V. |
| SHC | Sotera Health Company |
| ICLR | ICON Public Limited Company |
| RDNT | RadNet, Inc. |
| CSTL | Castle Biosciences, Inc. |
| NEOG | Neogen Corporation |
| PRE | Prenetics Global Limited |
| MEDP | Medpace Holdings, Inc. |
| BDSX | Biodesix, Inc. |
| OLK | Olink Holding AB (publ) |
| IQV | IQVIA Holdings Inc. |
| MYGN | Myriad Genetics, Inc. |
ACRS Ownership FAQ
Who Owns Aclaris Therapeutics?
Aclaris Therapeutics is owned by institutional shareholders (42.00%), insiders (2.55%), and public (55.45%). The largest institutional shareholder of Aclaris Therapeutics is BML CAPITAL MANAGEMENT, LLC (13.26% of total shares) and the top mutual fund owner is HARTFORD HLS SERIES FUND II INC (1.10% of total shares).
Who are the major institutional shareholders of Aclaris Therapeutics?
Aclaris Therapeutics's major institutional shareholders are BML CAPITAL MANAGEMENT, LLC, BLACKROCK INC., VANGUARD GROUP INC, D. E. SHAW & CO., INC., and MILLENNIUM MANAGEMENT LLC. The top five shareholders own together 36.81% of the company's share outstanding.
How many Aclaris Therapeutics shareholders are there?
As of Mar 2024, there are 51 institutional shareholders of Aclaris Therapeutics.
What percentage of Aclaris Therapeutics is owned by BML CAPITAL MANAGEMENT, LLC?
BML CAPITAL MANAGEMENT, LLC owns 9.4M shares of Aclaris Therapeutics, representing 13.26% of the company's total shares outstanding, valued at $11.65M (as of Mar 2024).
What percentage of Aclaris Therapeutics is owned by BLACKROCK INC?
As of Mar 2024, BLACKROCK INC holds 5.2M shares of Aclaris Therapeutics (ACRS), compromising 7.34% of the company, valued at $6.45M.
What percentage of Aclaris Therapeutics is owned by VANGUARD GROUP INC?
VANGUARD GROUP INC is the third largest holder of Aclaris Therapeutics. The company owns 4.93M of the company's shares outstanding (worth $6.11M).